Catalyst Dossier · compiled by CeliA 🧫

Tiziana Life Sciences Ltd (TLSA)

Pharmaceutical Preparations · market cap $146M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-07

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-07Earningsimp 5/10
2026-09-30Phase 2imp 6/10
2027-04-01 (est.)Phase 2 · Foralumab Nasalimp 7/10

Pipeline

Asset	Phase	Indication
Foralumab Nasal	Phase 2	Multiple System Atrophy
Foralumab	Phase 2	Secondary Progressive Multiple Sclerosis
Foralumab TZLS-401 100 µg	Phase 2	Non-Active Secondary Progressive Multiple Sclerosis
Milciclib maleate	Phase 2	Hepatocellular Carcinoma

Price & technical context

3-month

+4.8%

6-month

-14.9%

12-month

-15.5%

52-wk range

$1.08–$2.50

vs 50-day MA

-0.1%

vs 200-day MA

-14.2%

Realized vol

77.4%

Max drawdown

-56.8%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TLSA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.